Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
AI-Driven Wellness Play on the CSE (click to learn more) Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more) An Emerging Name in Cannabis: HERB (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Kamada Ltd KMDA

Healthcare Drug Manufacturers - Specialty & Generic
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:KMDA)

Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio

TheNewsWire January 13, 2026

Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

GlobeNewswire January 7, 2026

Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

GlobeNewswire December 18, 2025

Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

GlobeNewswire December 8, 2025

Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year

TheNewsWire November 18, 2025

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

GlobeNewswire November 10, 2025

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

GlobeNewswire November 4, 2025

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

GlobeNewswire November 3, 2025

Kamada to Present at the Stifel 2025 Healthcare Conference

GlobeNewswire October 29, 2025
View More News ››

Opinion & Analysis (NDAQ:KMDA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KMDA)

Where is everyone ? 1st post?

This could boom on Monday and there after 
TonyRask - August 15, 2020
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »

Podcasts